| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Prezentovaná studie má dva hlavní cíle. První je charakterizovat interakce antimikrobiálního peptidu (AMP) cryptdinu-4 (Crp-4) s biologickými membránami, a porovnat tyto interakce s interakcemi magaininu 2. Druhý je zkombinovat doplňkové experimentální přístupy laserové skenovací mikroskopie (LSM), elipsometrie a z-skenové fluorescenční korelační spektroskopie (FCS) pro získání obsáhlých informací ohledně mechanismu AMP interakcí s podporovanými fosfolipidovými dvojvrstvami (SPBs) – populárním modelem biologických membrán. LSM ukazuje vznik nehomogenit v prostorové distribuci lipidové dvojvrstvy po ošetření Crp-4. Elipsometrická měření ukazují, že vazba Crp-4 významně nemění lipidovou strukturu dvojvrstvy (vzrůst adsorbované hmoty bez změny tloušťky adsorbované vrstvy). Dále Crp-4 zpomaluje laterální difusi lipidů v membráně, jak ukazuje Z-skenovací FCS. Všechny změny dvojvrstvy vyvolané Crp-4 mohou být částečně obráceny vymytím vzorku nadbytkem pufru. (cs)
- The present study has two main objectives. The first is to characterize antimicrobial peptide (AMP) cryptdin-4 (Crp-4) interactions with biological membranes and to compare those interactions with those of magainin 2. The second is to combine the complementary experimental approaches of laser scanning microscopy (LSM), ellipsometry, and Z-scan fluorescence correlation spectroscopy (FCS) to acquire comprehensive information on mechanisms of AMP interactions with supported phospholipid bilayers (SPBs) - a popular model of biological membranes. LSM shows appearance of inhomogencities in spatial distribution of lipids in the bilayer after treatment with Crp-4. Ellipsometric measurements show that binding of Crp-4 does not significantly change the lipid structure of the bilayer (increase in adsorbed mass without a change in thickness of adsorbed layer). Furthermore, Crp-4 slows the lateral diffusion of lipids within the membrane as shown by Z-scan FCS.
- The present study has two main objectives. The first is to characterize antimicrobial peptide (AMP) cryptdin-4 (Crp-4) interactions with biological membranes and to compare those interactions with those of magainin 2. The second is to combine the complementary experimental approaches of laser scanning microscopy (LSM), ellipsometry, and Z-scan fluorescence correlation spectroscopy (FCS) to acquire comprehensive information on mechanisms of AMP interactions with supported phospholipid bilayers (SPBs) - a popular model of biological membranes. LSM shows appearance of inhomogencities in spatial distribution of lipids in the bilayer after treatment with Crp-4. Ellipsometric measurements show that binding of Crp-4 does not significantly change the lipid structure of the bilayer (increase in adsorbed mass without a change in thickness of adsorbed layer). Furthermore, Crp-4 slows the lateral diffusion of lipids within the membrane as shown by Z-scan FCS. (en)
|
| Title
| - Combination of ellipsometry, laser scanning microscopy and Z-scan fluorescence correlation spectroscopy elucidating interaction of cryptdin-4 with supported phospholipid bilayers
- Kombinace elipsometrie, laserové skenovací mikroskopie a Z-skenové fluorescenční korelační spektroskopie objasňuje interakci cryptdinu-4 s podporovanými fosfolipidovými dvojvrstvami (cs)
- Combination of ellipsometry, laser scanning microscopy and Z-scan fluorescence correlation spectroscopy elucidating interaction of cryptdin-4 with supported phospholipid bilayers (en)
|
| skos:prefLabel
| - Combination of ellipsometry, laser scanning microscopy and Z-scan fluorescence correlation spectroscopy elucidating interaction of cryptdin-4 with supported phospholipid bilayers
- Kombinace elipsometrie, laserové skenovací mikroskopie a Z-skenové fluorescenční korelační spektroskopie objasňuje interakci cryptdinu-4 s podporovanými fosfolipidovými dvojvrstvami (cs)
- Combination of ellipsometry, laser scanning microscopy and Z-scan fluorescence correlation spectroscopy elucidating interaction of cryptdin-4 with supported phospholipid bilayers (en)
|
| skos:notation
| - RIV/61388955:_____/08:00311018!RIV09-AV0-61388955
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(GA203/05/2308), P(GD203/05/H001), P(LC06063), Z(AV0Z40400503)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61388955:_____/08:00311018
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - cryptdin-4; megainin 2; supported phospholipid bilayers; ellipsometry (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Journal of Peptide Science
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Hof, Martin
- Macháň, Radek
- Benda, Aleš
- Miszta, Adam
- Hermens, W. Th.
- Ouellette, A. J.
|
| http://linked.open...ain/vavai/riv/wos
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)